Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms
Byooviz Biosimilar Backed By EMA Committee In June
Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.
